-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

Benzinga·08/12/2026 12:33:00
Listen to the news
Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.